Opinion: Supporting long COVID patients and the people caring for them
Squamish Chief,
We are living through a mass-disabling event: Over 200 million people worldwide have long COVID.
Showing items 1–100
Opinion: Supporting long COVID patients and the people caring for them
Vancouver Is Awesome,
Although millions are navigating long COVID, four years into the pandemic both patients and their caregivers continue to face…
Making visible the invisible: Supporting long COVID patients and the people caring for them
MSN,
We are living through a mass-disabling event: Over 200 million people worldwide have long COVID.
Making visible the invisible: Supporting long COVID patients and the people caring for them
MedicalXpress,
We are living through a mass-disabling event: Over 200 million people worldwide have long COVID.
MIL-OSI Global: Making visible the invisible: Supporting long COVID patients and the people caring...
Foreign Affairs New Zealand,
The prevalence of long COVID — a multi-system chronic illness occurring weeks to months after a COVID-19 infection — has led to…
Making visible the invisible: Supporting long COVID patients and the people caring for them
The Conversation,
We are living through a mass-disabling event: Over 200 million people worldwide have long COVID.
News story from Big News Network on Monday 24 June 2024
Big News Network,
Vaccination significantly reduces the risk of long-term effects from Covid-19 - Verve times
Verve times,
At least 200 million people worldwide have struggled with long COVID: a slew of symptoms that can persist for months or even…
Vaccines slash danger of lengthy COVID, research present
PressNewsAgency,
No less than 200 million individuals worldwide have struggled with lengthy COVID: a slew of signs that may persist for months…
La vacunación reduce drásticamente el riesgo de Covid a largo plazo
Espanol.news,
3 de enero de 2024 4 lectura mínima Varios estudios nuevos revelan que recibir múltiples dosis de la vacuna COVID proporciona…
Vaccination Dramatically Lowers Long Covid Risk
Scientific American,
January 3, 2024 4 min read Several new studies reveal that getting multiple COVID vaccine doses provides strong protection…
A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir–Ritonavir for COVID-19 in an interdisciplinary community clinic
PLoS Medicine,
by Valerie Leung, Suzanne Gill, Andrea Llanes, Armughan Khawaja, Amanda Stagg, Janine McCready, Mariana Jacubovich, Grace Ho…
果壳 整天觉得又累又困，或许跟你去年“阳过”有关！ 仍然是个好理由 果壳果壳网官方帐号
Guokr.com,
收录于合集 新冠病毒感染后几个月，还有疲劳、咳嗽、记忆力下降等问题？你不是一个人。 根据世界卫生组织官网，感染新冠三个月后仍未根治的症状，或者康复后又出现的症状，持续2个月以上，且排除其他诱因，可以归为新冠后遗症（“长新冠”）。不同研究对其普遍程度估算不一…
News story from EX BULLETIN on Thursday 24 August 2023
EX BULLETIN,
News story from Stat News on Wednesday 23 August 2023
Stat News,
Stephenie could not get her legs to move in sync. Turns out it was long COVID
Brisbane Times,
Nic Goodrich is an exercise junkie. The 45-year-old would hit the iron three or four nights a week, then walk the dog five…
News story from The Age on Wednesday 19 April 2023
The Age,
News story from Sydney Morning Herald on Wednesday 19 April 2023
Sydney Morning Herald,
News story from Western Australia Today on Wednesday 19 April 2023
Western Australia Today,
Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study
The Lancet,
BackgroundAdults and children can develop post-Covid-19 condition (PCC) (also referred to as Long Covid).
Structural brain changes in patients with post-COVID fatigue: a prospective observational study
The Lancet,
BackgroundPost-COVID syndrome s a severe long-term complcaton of COVID-19. Although fatgue and cogntve complants are the most…
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
USA Life Sciences Database,
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage…
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
Biz Wire Express,
GlobeNewswire 2023-02-22 BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC.
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
MarketScreener,
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company…
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
GlobeNewswire,
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage…
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
Benzinga,
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. BIXT (the "Company"), a clinical stage biotechnology…
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
Yahoo! Finance USA,
BOSTON, MASSACHUSETTS, Feb. 22, 2023 BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company…
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
Biospace,
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage…
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
KTLA,
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage…
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
News Channel 11 wjhl.com,
News provided by BIOXYTRAN, INC. Feb 06, 2023, 9:00 AM ET BOSTON, MASSACHUSETTS, Feb.
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
GlobeNewswire,
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage…
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
Yahoo! Finance USA,
BOSTON, MASSACHUSETTS, Feb. 06, 2023 BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company…
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
Biospace,
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage…
Long-Term Cardiometabolic Impacts of COVID-19 | The Institute for Functional Medicine
Functional Medicine News & Emerging Research,
Read Time: 4 Minutes For most patients who test positive for COVID-19, symptoms improve or resolve within days or weeks.
News story from EX BULLETIN on Monday 05 December 2022
EX BULLETIN,
Why does COVID-19 cause brain fog? Scientists may finally have an answer.
NationalGeographic.co.uk,
When scientists at the Karolinska Institute in Sweden infected brain organoids—pinhead-size bits of brain tissue grown in the…
Why does COVID-19 cause brain fog? Scientists may finally have an answer. - journalbreak
journalbreak.Com,
When scientists at the Karolinska Institute in Sweden infected brain organelles — lab-grown pieces of brain tissue the size of…
Why does COVID-19 cause brain fog? Scientists may finally have an answer.
National Geographic,
Science Coronavirus Coverage Nearly 40 percent of long COVID patients suffer from the disorienting condition.
Hospitalized or Not, COVID Symptoms Persist in Many After 2 Years
MedPage Today,
Infectious Disease > Long COVID Fatigue, pain, and memory loss cited most frequently by Ingrid Hein, Staff Writer, MedPage…
Has Long COVID Always Existed?
New York Magazine,
The pandemic might not have spawned a new chronic illness but rebranded an old one.
Natural Ways to Increase Autophagy and Detox Spike Proteins After COVID Infection, Vaccination
The Epoch Times,
At least 10 to 30 percent of individuals infected by SARS-CoV-2 have experienced post-COVID syndrome (also known as long-hauler…
COVID-19 y la vacuna pueden causar psicosis, la musicoterapia podría ayudar
Lagranepoca.com,
La musicoterapia puede ayudar a las personas que sufren de psicosis inducida por COVID de larga duración.
AskByGeeks | Opinion | After the pandemic, heavy burdens for a covid generation
AskByGeeks,
Ask anyone who has experienced the lingering maladies of the pandemic, and they’ll tell you long covid is no figment of the…
After the pandemic, heavy burdens for a covid generation
Washington Post,
Ask anyone who has experienced the lingering maladies of the pandemic, and they’ll tell you long covid is no figment of the…
Mais de 6% dos doentes covid-19 apresentam covid longa — mas o número pode ser bem maior
Observador,
Novo estudo estima que 2,4 a 13,3% dos doentes covid-19 sintomáticos terão pelo menos um de três grupos de sintomas ao fim de trê…
Multiple Possible Causes of Long COVID Come into Focus
The Scientist Magazine,
Recent studies have lent support for a variety of hypotheses explaining the debilitating symptoms affecting millions of people…
Researcher proposes national program to support individuals with long COVID
Today UK News,
Credit: Pixabay/CC0 Public Domain While the COVID-19 pandemic wanes, the U.S. continues to face a national health challenge—the…
It’s Time To Create A National Long COVID Compensation Program
KNEWS,
The US faces a national health challenge—the effective and equitable care of millions of individuals with long COVID.
AskByGeeks | It’s Time To Create A National Long COVID Compensation Program
AskByGeeks,
The US faces a national health challenge—the effective and equitable care of millions of individuals with long COVID.
BU researcher urges the U.S. to commit to create a a National Long COVID Compensation Program
The Medical News,
While the COVID-19 pandemic wanes, the U.S. continues to face a national health challenge – the effective and equitable care of…
Researcher proposes national program to support individuals with long COVID
MedicalXpress,
Credit: Pixabay/CC0 Public Domain While the COVID-19 pandemic wanes, the U.S. continues to face a national health challenge—the…
BU researcher proposes national program to support individuals with long COVID
EurekAlert!,
Would address medical treatment as well as disability insurance (Boston)While the COVID-19 pandemic wanes, the U.S.
Researcher proposes national program to support individuals with long COVID
Mirage News,
Boston University School of Medicine Would address medical treatment as well as disability insurance (Boston)—While the COVID-19…
It's Time To Create A National Long COVID Compensation Program
Health Affairs,
The US faces a national health challenge—the effective and equitable care of millions of individuals with long COVID.
Researcher proposes national program to support individuals with long COVID
Sciencenewsnet.in,
Post Views: 17 (Boston)While the COVID-19 pandemic wanes, the U.S. continues to face a national health challenge the effective…
Researcher proposes national program to support individuals with long COVID
Newswise,
Newswise — (Boston)—While the COVID-19 pandemic wanes, the U.S. continues to face a national health challenge – the effective…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Everything Lubbock,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
KTLA,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
News story from News Channel 8 on Monday 29 August 2022
News Channel 8 ,
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Kxan,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
ABC27,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
FOX31 Denver KDVR-TV,
Please enter a search term. Please enter a search term. News provided by Aug 29, 2022, 11:05 AM ET BALDWIN PARK, Calif., Aug.
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
WGN9,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Your Basin,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
KOIN 6,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
News Channel 11 wjhl.com,
News provided by StemCyte Aug 29, 2022, 11:05 AM ET BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
abc8news,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Ticker Tech,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
ProfitQuotes.com,
BALDWIN PARK, Calif., Aug. 29, 2022 -- Southern California cord blood regenerative therapeutics company StemCyte is pleased to…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
AP News,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
WISTV,
StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair.
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Wave 3 News,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Benzinga,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
WSFA ,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Hawaii News Now,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
WTVM,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
WLOX,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
NBC12,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Yahoo! Finance USA,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ Southern California cord blood regenerative therapeutics company StemCyte is…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
KCBD,
Published: Aug. 29, 2022 at 10:05 AM CDT|Updated: 10 minutes ago BALDWIN PARK, Calif., Aug.
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Fox 19,
Published: Aug. 29, 2022 at 11:05 AM EDT|Updated: 9 minutes ago BALDWIN PARK, Calif., Aug.
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
News Channel 10,
Published: Aug. 29, 2022 at 10:05 AM CDT|Updated: 9 minutes ago BALDWIN PARK, Calif., Aug.
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Morning Star,
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
WALB,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
KBTX-TV,
Published: Aug. 29, 2022 at 10:05 AM CDT|Updated: 12 minutes ago BALDWIN PARK, Calif., Aug.
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
WBRC,
, - Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
KCRG.com,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
PR Newswire,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Yahoo!,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Biospace,
BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte…
Jab injuries, 50% long COVID cases have this type of symptom – 2 ways to reverse it
WooDZog.com,
Many people experience “prolonged COVID” symptoms after an acute bout of COVID-19 infection.
Jab Injuries, 50% Long COVID Cases Have This Type of Symptom—2 Ways to Reverse It
awsforwp,
Many people experience “long COVID” symptoms after an acute attack of COVID-19 infection.
News story from EX BULLETIN on Monday 22 August 2022
EX BULLETIN,
Our Price for Not Aiming Higher: Long COVID Is Here to Stay
Contagion Live ,
As COVID-19 headlines ebb and flow in the United States, the virus keeps charging forward.
News story from AllAfrica on Friday 19 August 2022
AllAfrica,
News story from Big News Network on Thursday 18 August 2022
Big News Network,
Friday essay: how a bike accident changed me, by a philosopher of hope
Newsbreak,
- NewsBreak Cycling once made me feel free unlike anything else. I loved the sensation of slicing through the air, flying past…
Friday essay: how a bike accident changed me, by a philosopher of hope
Yahoo! News,
Cycling once made me feel free unlike anything else. I loved the sensation of slicing through the air, flying past pedestrians…
Friday essay: how a bike accident changed me, by a philosopher of hope
The Conversation,
Cycling once made me feel free unlike anything else. I loved the sensation of slicing through the air, flying past pedestrians…
Why Long COVID and Vaccine Injuries Look so Similar: Expert Explains
The Epoch Times,
Brianne Dressen has never been infected with the SARS-CoV-2 virus. After she was given the AstraZeneca (AZ) vaccine in a…
Showing items 1–100